Phase 2 Trial of Brigatinib after Treatment with Second - Generation ALK Inhibitors in Refractory
ALK Rearranged NSCLC
Not exact matches
How the Study Was Conducted and Results: Farace and colleagues prospectively recruited 39 patients with
ALK -
rearranged NSCLC to the study.
[38] A retrospective study of 90 patients with
ALK -
rearranged NSCLC metastatic to the brain found that OS after the development of brain metastases was still prolonged at approximately 4 years (49.5 months), with patients frequently having multiple opportunities for salvage SRS at recurrence; 45 % of patients on follow - up had progressive brain metastases at death.
Extended survival and prognostic factors for patients with
ALK -
rearranged non-small-cell lung cancer and brain metastasis.